2022
Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.Peer-Reviewed Original ResearchConceptsSelf-reported COVID-19 infectionCOVID-19 infectionOncology meetingsEra of vaccinationCOVID-19 positivityCOVID-19 positivity ratesOncology annual meetingsPerson attendeesAmerican SocietyCOVID-19Risk of diseasePerson meetingsPositivity rateNew COVID-19 infectionsResponse rateEvent ratesSocial distancing mandatesHematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative
Makhoul I, Anders M, Siegel R, Chiang A, Markham MJ, Chen RC, Mougalian S, Arnaoutakis K, Giuliani M, Im A, Kozlik MMP, Crist STS, Garrett-Mayer E, Kamal A. Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. JCO Oncology Practice 2022, 18: e1209-e1218. PMID: 35467961, DOI: 10.1200/op.21.00807.Peer-Reviewed Original ResearchConceptsQuality Oncology Practice InitiativeEducational benefitsQI projectQuality improvement projectElectronic medical recordsPractice initiativesQI participationGraduate Medical Education requirementsFellowship programsMedical Education requirementsManual data abstractionMedical recordsMajority of programsOncology ProgramOncology fellowsACGME standardsEducation requirementsFaculty involvementAccreditation CouncilLongitudinal reports
2021
Novel Tool to Monitor Adherence to Oral Oncolytics: A Pilot Study.
Sun W, Reeve R, Ouellette T, Stutsky M, De Jesus R, Huffer MJ, Mougalian SS. Novel Tool to Monitor Adherence to Oral Oncolytics: A Pilot Study. JCO Clinical Cancer Informatics 2021, 5: 701-708. PMID: 34166064, DOI: 10.1200/cci.20.00151.Peer-Reviewed Original ResearchConceptsPilot studyCases of nonadherenceOral chemotherapy agentsCategory of patientsText message interventionMedication-taking behaviorCategory 2Category 3Category 1Cyclical regimenOral therapyOral oncolyticsCancer carePreintervention stageSuch therapyChemotherapy agentsAverage adherenceHigh riskPost interventionPatientsNonadherenceAdherencePrescription bottlesIntervention stageCapecitabinePatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefitEffectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2213-2225. PMID: 33491157, PMCID: PMC8107067, DOI: 10.1007/s12325-020-01613-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerMetastatic breast cancerObjective response rateProgression-free survivalMedian progression-free survivalMedian overall survivalOverall survivalBreast cancerClinical practiceRetrospective chart review studyReal-world clinical experienceReal-world clinical practiceUS indicationEffectiveness of eribulinThird-line therapyPatient chart reviewChart review studyReal-world effectivenessNegative breast cancerElectronic case report formCase report formsEligible patientsMetastatic settingChart reviewTreatment landscape
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsText Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer
Pusztai L, Taylor R, Mougalian SS. Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. Cancer Cell 2020, 38: 323-325. PMID: 32931742, DOI: 10.1016/j.ccell.2020.08.006.Peer-Reviewed Original ResearchPatient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development
Schulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang S, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development. The Patient - Patient-Centered Outcomes Research 2020, 13: 683-697. PMID: 32508006, DOI: 10.1007/s40271-020-00426-7.Peer-Reviewed Original ResearchConceptsFamily caregiversTreatment optionsDecision regretHealth care system issuesEarly breast cancer treatmentCaregiver considerationsCancer treatment patternsInitial definitive treatmentClinical pathway developmentBreast cancer treatmentFamily caregivers' perspectivesConsideration of patientsDecision pathwaysFindings patientsDefinitive treatmentTreatment patternsSpouse/partnerBreast cancerClinical pathwayTreatment decisionsCancer statusPatientsStage ICaregiver perspectivesTreatment plan